Evotec Q4 2025 slides: strong finish masks segment headwinds

Evotec reported Q4 revenue of €253.3m (+14.5% YoY) and adjusted Group EBITDA of €58.0m (more than doubled YoY); full-year 2025 revenue was €788.4m with adjusted EBITDA €41.1m, while JEB drove performance—JEB revenues rose 39.8% to €259.4m and the company closed a landmark $650m Sandoz transaction. Management launched the 'Horizon' transformation targeting ~€75m run-rate cost savings by end-2027, plans to cut ~800 roles and reduce sites from 14 to 10, and expects ~€100m cash restructuring costs in H2 2026; 2026 guidance is €700-780m revenue and €0-40m adjusted EBITDA with ~3.5% FX headwinds. Liquidity strengthened to €476m with net cash €40m, but core D&PD revenue declines (down 13.5% to €528.9m) and near-term execution risk on restructuring and asset monetization remain key downside factors.

Analysis

The market is rewarding a clear narrative shift: proprietary, capital-light biologics technology can re-anchor a legacy drug-discovery platform that otherwise struggles with structural overcapacity. The second-order lever here is monetization optionality — realized cash from strategic exits and licensing not only funds restructuring but also derisks burn, turning a balance-sheet story into an operating leverage story if management executes.

Competitive dynamics favor companies that can convert one-off validation deals into repeatable licensing frameworks; rivals that remain asset-heavy CMOs will see margin compression if Evotec proves a scalable tech-licensing pathway. Conversely, small discovery boutiques that rely on fee-for-service models could face pricing pressure as buyers push for outcomes and lower fixed-capacity exposure.

Execution risk is front-loaded: most value accrues only if site consolidations, headcount reductions, and commercial upgrades deliver within the 18–36 month window and FX pressures stabilize; missed timing or larger-than-guided restructuring cash burn would re-open refinancing and equity-dilution risk. Watch near-term cadence of milestone realizations from partnered programs and any acceleration of equity-portfolio monetizations — those are the binary catalysts that flip this from a narrative trade into realized returns.

Key Decisions for Investors

• Long EVO (core position, 12–24 months): Initiate on a market pullback or on confirmation of one or two Horizon milestones (site closure announcements or first tranche of restructuring cash outflow booked). Position size: 1–2% of portfolio. Risk management: 30% stop from entry; target asymmetric return of 60–100% if JEB licensing repeats and D&PD stabilizes.
• Long-dated call spread on EVO (18 months): Buy a 18-month call ~moderately OTM and sell a higher strike to finance (~decently OTM). Rationale: convex exposure to JEB commercialization + limited premium lost if D&PD softness persists. Max loss = net premium; asymmetric upside if milestones and monetizations materialize.
• Relative-value pair (12–36 months): Long EVO / Short a scale-focused CDMO (e.g., Lonza or Catalent) to express tech-licensing vs capacity-led model. Size to net 0.5–1% portfolio. Thesis: if licensing becomes repeatable, Evotec re-rates; downside if broad CDMO demand recovery occurs — cap pair exposure and rebalance after major news.
• Volatility hedge (30–90 days): If shares gap up post-news, sell short-dated premium (~2–4 weeks) against core position or buy protective puts to limit near-term downside from execution misses. Use this to monetize elevated IV while retaining long-term exposure.